Abstract
Growth hormone deficiency (GHD) in children causes decreased growth and markedly reduced adult height. The treatment for GHD has been given as daily subcutaneous injections. However, new GH formulations can be given weekly. Injections are a burden for children and caregivers, but to our knowledge, the impact on quality of life (QoL) has not been investigated using time trade-off (TTO) methodology. This study evaluates the impact of type of injections on QoL using a TTO survey.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
